Is there evidence that the Osteoboost device helps maintain or improve bone density in postmenopausal women with low bone mass?

No Evidence Supports Osteoboost for Bone Density Improvement

There is no credible scientific evidence that the Osteoboost device maintains or improves bone mineral density in postmenopausal women with low bone mass. A 2025 scoping review specifically examining OsteoStrong (the proprietary system that includes devices marketed under various names including Osteoboost) found the research is "mainly limited to small observational studies that are at risk of bias" with "inconsistent" effects on bone mineral density 1.

Critical Evidence Gaps

The OsteoStrong/Osteoboost research base is fundamentally flawed 1:

• No randomized controlled trials comparing the device to a true control group exist
• Most studies have small sample sizes and significant conflicts of interest
• The two largest studies included participants already taking anti-resorptive medications (confounding the results)
• Several studies were published in predatory journals or remain unpublished abstracts
• Only 2 trials reported on fractures, falls, or adverse events—the outcomes that actually matter for patient morbidity and mortality

The effects on BMD were inconsistent across trials, and there is little safety data 1. This is particularly concerning given that the device claims to work with just 10 minutes weekly—a claim that contradicts established bone physiology.

What Actually Works: Evidence-Based Alternatives

Instead of unproven devices, the 2023 American College of Physicians guidelines provide clear direction 2:

First-Line Treatment

Bisphosphonates (alendronate, risedronate, zoledronate) should be the initial pharmacologic treatment for postmenopausal women with osteoporosis 2. These medications:

• Have high to moderate certainty evidence for fracture reduction
• Are available as inexpensive generics
• Have well-characterized safety profiles
• Reduce vertebral fractures by 140 per 1000 treated patients 2

Second-Line Options

Denosumab (60 mg subcutaneously every 6 months) serves as an alternative for women who cannot tolerate bisphosphonates 3.

Very High-Risk Patients

For women with severe or multiple vertebral fractures, teriparatide or abaloparatide for up to 2 years reduces both vertebral and nonvertebral fractures 3.

Exercise That Actually Has Evidence

While Osteoboost lacks credible data, other exercise interventions show more promise:

• Whole-body vibration has some evidence for lumbar spine BMD improvement in specific protocols (12.5 Hz rotational or 35 Hz vertical vibration, 3 sessions weekly) 4, though effects remain modest (+0.5-0.7% BMD gain)
• High-impact jumping exercises (10 maximal countermovement jumps, 3 times weekly) are feasible and well-tolerated but show only a 3% BUA increase without statistical significance 5

However, these interventions should be adjuncts to pharmacologic therapy, not replacements 3.

Clinical Bottom Line

Do not recommend Osteoboost to patients with osteoporosis or low bone mass. The device lacks the rigorous evidence required to justify its use when proven pharmacologic treatments exist. The 2019 Endocrine Society guidelines emphasize that "multiple pharmacologic therapies are capable of reducing fracture rates in postmenopausal women at risk with acceptable risk-benefit and safety profiles" 3—Osteoboost is not among them.

For postmenopausal women with low bone mass:

1. Assess fracture risk using validated tools (FRAX)
2. Prescribe bisphosphonates as first-line therapy for high-risk patients 2
3. Ensure adequate calcium and vitamin D as adjunctive therapy 3
4. Encourage evidence-based exercise (weight-bearing, resistance training) alongside medication
5. Monitor BMD every 1-3 years with DXA scanning 3

The marketing claims of devices like Osteoboost exploit patients' desire for non-pharmacologic solutions, but fracture prevention requires interventions with proven efficacy for reducing morbidity and mortality—not unvalidated proprietary equipment.